This roundtable series explores therapies available for patients with differentiated thyroid cancer after they have radioactive iodine-refractory disease, as discussed by key opinion leaders at virtual live events and interviews.

Differentiated Thyroid Cancer Treated After Radioactive Iodine Therapy

Applying Guideline Recommendations for Advanced Thyroid Cancer

November 05, 2025

During a live event, Lori Wirth, MD, discussed preferred treatment for thyroid cancer with and without a RET, NTRK, or ALK fusion.

Treating Metastatic DTC After Radioactive Iodine Progression

October 22, 2025

During a live event, Lori Wirth, MD, discussed next steps for treating a patient with progressive, radioactive iodine–refractory differentiated thyroid cancer.

Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC

December 05, 2024

During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.

$SELECT Trial Outcomes Support Lenvatinib as RAI-Refractory DTC Therapy$

SELECT Trial Outcomes Support Lenvatinib as RAI-Refractory DTC Therapy

November 11, 2024

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in differentiated thyroid cancer in the first article of a 2-part series.